Zobrazeno 1 - 10
of 26
pro vyhledávání: '"David Oldach"'
Autor:
Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A. Hay, Patrick Smith, Frank Engler, Rienk Jeeninga, Saskia Smits, Jose Trevejo, Zach Shriver, David Oldach
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 574-582 (2019)
Background: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non
Externí odkaz:
https://doaj.org/article/05bb3efbad9847a08d9ae6f127d94fdb
Autor:
Mohit Mathur, Jonathan Barratt, Yusuke Suzuki, Frank Engler, Marcela F. Pasetti, Jill Yarbrough, Susan Sloan, David Oldach
Publikováno v:
Kidney International Reports. 7:993-1003
Autor:
Mohit, Mathur, Jonathan, Barratt, Yusuke, Suzuki, Frank, Engler, Marcela F, Pasetti, Jill, Yarbrough, Susan, Sloan, David, Oldach
Publikováno v:
Kidney international reports. 7(5)
VIS649 (sibeprenlimab), a humanized IgGParticipants were randomized to VIS649 (sequential i.v. dosing cohorts: 0.5, 2.0, 6.0, 12.0 mg/kg) or placebo; a further cohort received VIS649 6.0 mg/kg or placebo followed by a tetanus/diphtheria vaccine chall
Autor:
Frank Engler, Yusuke Suzuki, David Oldach, Susan Sloan, Jonathan Barratt, Jill Yarbrough, Mohit Mathur
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Immunoglobulin A (IgA) nephropathy (IgAN) is a glomerulonephritis characterized by the presence of circulating and glomerular immune complexes containing galactose-deficient (Gd) IgA1. A proliferation-inducing ligand (APRIL), a me
Autor:
Susan Sloan, Yusuke Suzuki, David Oldach, Jonathan Barratt, Frank Engler, Jill Yarbrough, Mohit Mathur
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims VIS649, a humanized immunoglobulin G (IgG2) monoclonal antibody that binds to and blocks the biological actions of a proliferation-inducing ligand (APRIL), is in clinical development as a potential treatment for immunoglobulin A (
Autor:
Catriona S. Bradshaw, Sepehr N. Tabrizi, Basil Donovan, Ashley Nenninger, Ann Avery, David Oldach, Jane S Hocking, Dwight J. Hardy, Christopher K Fairley, Marcus Y Chen, Benjamin P Howden, David M. Whiley, Anita Das, Anna McNulty
Publikováno v:
The Lancet Infectious Diseases. 19:833-842
Summary Background Antibiotic-resistant gonorrhoea represents a global public health threat, and new therapies are needed. We aimed to compare the efficacy and safety of solithromycin, a fourth generation macrolide, with ceftriaxone plus azithromycin
Autor:
Robert D. Kirkcaldy, Robert A. Nicholas, Yonatan H. Grad, Peter A. Rice, David Oldach, Jeffrey D. Klausner, Anthony D. Cristillo, Huan V. Dong, Claire C. Bristow, Kenneth Lawrence, Elizabeth Torrone, Teodora Wi, Jo-Anne R. Dillon, Pei Zhou, William M. Shafer, Sheldon R. Morris
Publikováno v:
Sexually transmitted diseases
Sexually transmitted diseases, vol 46, iss 3
Sexually transmitted diseases, vol 46, iss 3
The goal of the Sexually Transmitted Infection Clinical Trial Group’s (STI-CTG) Antimicrobial Resistance (AMR) in Neisseria gonorrhoeae (NG) meeting was to assemble experts from academia, government, non-profit and industry to discuss the current s
Autor:
Patrick F. Smith, Susan Sloan, Ellie Hershberger, David Oldach, Saskia Smits, Zach Shriver, Catherine A. Hay, Rienk E. Jeeninga, Frank Engler, Jose M. Trevejo, Kristin Narayan
Publikováno v:
EBioMedicine, Vol 40, Iss, Pp 574-582 (2019)
EBioMedicine
EBioMedicine
Background: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non
Autor:
David Oldach, Zachary Shriver, Susan Sloan, Sylvain Bedard, Kristin Narayan, Patrick F. Smith, Jose M. Trevejo, David Skurnik, Kristy J. Szretter, Bharathi Sundaresh
Publikováno v:
Antiviral Research. 184:104763
Influenza A infections cause significant seasonal morbidity and mortality as well as periodic pandemic infections. Currently, no approved therapies exist for patients hospitalized with influenza. The efficacy of VIS410, a broadly neutralizing human i
Autor:
Dirkie Johanna Van Rensburg, Prabhavathi Fernandes, Carlos Barrera, Anita Das, Ismail Mitha, Pablo Alexis Doreski, Kay Clark, Kara Keedy, Jose Flores-Figueroa, Barbara Rewerska, Brian D. Jamieson, Amanda Sheets, David Oldach, Najumuddin Karimjee, Hristo Metev, Yuri Antonovsky, Joseph McDermott Molina, Cristina Mihaela Tanaseanu, Gary Horwith, Analia Mykietiuk, Mimi Floarea Nitu, Brian H. Rowe, Drusilla Scott
Publikováno v:
The Lancet Infectious Diseases. 16:421-430
Summary Background Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality, and treatment recommendations, each with specific limitations, vary globally. We aimed to compare the efficacy and safety of solithromycin